DPP-4 inhibitor for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 severe or critically meta-analysis
Abuhasira NCT04371978		RCT	DPP-4 inhibitor	standard of care	COVID-19 severe or critically	some concern	32/32	inconclusive	inconclusive 70 % increase in clinical improvement (28-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
3 studies excluded by filtering options (0 RCT / 3 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 severe or critically meta-analysis